1442425-00-4

Upstream product

• 1121-60-4 pyridine-2-carbaldehyde 
• 1442432-62-3 1-(cyclohexylmethyl)-2-methyl-5-(1-(piperidin-1-ylsulfonyl)indolizin-3-yl)-1H-pyrrole-3-carboxylic acid 
• 153209-97-3 (3-methyloxetan-3-yl)methanamine 
• 1442432-61-2 ethyl 1-(cyclohexylmethyl)-2-methyl-5-(1-(piperidin-1-ylsulfonyl)indolizin-3-yl)-1H-pyrrole-3-carboxylate 
• 1442432-60-1 ethyl 1-(cyclohexylmethyl)-5-(1-(N-(methoxycarbonyl)sulfamoyl)indolizin-3-yl)-2-methyl-1H-pyrrole-3-carboxylate 
• 1442432-59-8 ethyl 1-(cyclohexylmethyl)-2-methyl-5-(3-(pyridin-2-yl)propanoyl)-1H-pyrrole-3-carboxylate 
• 952396-45-1 ethyl 1-(cyclohexylmethyl)-2-methyl-1H-pyrrole-3-carboxylate 
• 1442432-57-6 ethyl 5-acetyl-1-(cyclohexylmethyl)-2-methyl-1H-pyrrole-3-carboxylate 

Relevant academic research and scientific papers

PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR?, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES

The invention provides modulators for the orphan nuclear receptor ROR? and methods for treating ROR? mediated diseases by administrating these novel ROR? modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo carboxamide compounds of Formula (1) and the enantiomers, diastereomers, N-oxides, tautomers, solvates and pharmaceutically acceptable salts thereof.